Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 132 posts found.

jj_2johnson_and_johnson

Actelion acquisition hokey-cokey continues with J&J returning to table

December 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …

News

J&J’s largest India site to finally operate by 2018

December 20, 2016
Manufacturing and Production India, Johnson & Johnson

Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is …

News
actelion

Sanofi eyes Actelion merger as J&J backs down

December 14, 2016
Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while …

News
jj_2johnson_and_johnson

J&J and Genmab’s drug races to second line treatment approval

November 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …

News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …

News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016
Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …

News
janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

News
code

BenevolentAI announces licensing agreement with Janssen

November 8, 2016
Research and Development Janssen, Johnson & Johnson, artificial intelligence

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, …

News
pfizer_sky

Pfizer sets release date for rival to J&J’s blockbuster drug

October 18, 2016
Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News
jj_2johnson_and_johnson

Patients’ insulin pumps are revealed to be hackable by J&J

October 4, 2016
Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …

News
jj_2johnson_and_johnson

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

October 3, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …

News
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

News
jj_2johnson_and_johnson

Johnson & Johnson’s Stelara receives FDA approval

September 27, 2016
Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara

The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …

News
jj_sign_on_wall

J&J in $4.33bn eye surgery unit acquisition

September 19, 2016
Manufacturing and Production, Sales and Marketing Abbott, Johnson & Johnson, acquisition

Johnson & Johnson has agreed to buy Abbott Laboratories’ eye surgery equipment unit in an all-cash deal for £4.33 billion …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023